Identification of D motif epitopes in Staphylococcus aureus fibronectin-binding protein for the production of antibody inhibitors of fibronectin binding.
A fibronectin-binding protein (FnBP) adhesin of Staphylococcus aureus possesses three 37- or 38-amino-acid motifs (D1, D2, and D3) that can each bind fibronectin (Fn) with low affinity and that in tandem comprise D1-3, a high-affinity Fn-binding domain. To identify epitopes for the generation of adhesion-blocking antibodies, rabbits were immunized with recombinant D1-3 or with a glutathione S-transferase fusion protein, GSTD1-3. Affinity-purified antibodies from the D1-3 immunization were poor inhibitors of Fn binding to S. aureus and recognized several different epitopes, with a preference for clusters of acidic amino acids that do not contribute to Fn binding. Antibodies generated with GSTD1-3 as an immunogen were more effective inhibitors, but concentrations in excess of 20 microg x ml-1 did not promote more than 50% inhibition. These antibodies were highly specific for amino acids 21 to 34 of D1 (D1(21-34)), which contain a sequence that is essential for Fn binding and are identical to D2 at 12 of 14 residues. Neither antibody preparation recognized D3(20-33) of the D3 motif, where the only homology to D1(21-34) and D2(21-34) comprises a sequence motif, GG(X3,4)(I/V)DF, that is critical to Fn binding. However, antibodies specific for both D1(21-34) and D3(20-33) could be obtained by using synthetic peptides corresponding to these sequences as immunogens. F(ab')2 fragments derived from these antibodies each caused 40 to 50% inhibition of Fn binding to S. aureus, and their ability to bind to purified FnBP was eliminated by competing Fn. However, mixtures of the two F(ab')2 preparations did not provide additive or synergistic inhibition of Fn binding. Therefore, inhibition of Fn binding to S. aureus requires antibodies specific for D1(21-34) and D3(20-33), but a mixture of antibodies specific for both sequences did not provide complete inhibition.
Sun
Q
Q
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
Smith
G M
GM
Zahradka
C
C
McGavin
M J
MJ
D018829:Adhesins, Bacterial; D000595:Amino Acid Sequence; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000494:pharmacology; D019138:Antibodies, Blocking / Q000096:biosynthesis* / Q000494:pharmacology; D000915:Antibody Affinity; D000918:Antibody Specificity; D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry* / Q000276:immunology* / Q000302:isolation & purification; D001426:Bacterial Proteins; D002352:Carrier Proteins; D000939:Epitopes / Q000737:chemistry* / Q000276:immunology* / Q000302:isolation & purification; D005353:Fibronectins / Q000378:metabolism*; D008969:Molecular Sequence Data; D011485:Protein Binding / Q000276:immunology; D011817:Rabbits; D013211:Staphylococcus aureus / Q000737:chemistry / Q000276:immunology*
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D019138:Antibodies, Blocking; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D002352:Carrier Proteins; D000939:Epitopes; D005353:Fibronectins; C078635:fibronectin-binding proteins, bacterial